{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:42:15Z","timestamp":1784860935419,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Various organisms, such as bacteria, viruses, and fungi, can cause corneal ulcers. One of the leading causes of vision loss and disability worldwide is corneal ulceration. Practical, accessible, and affordable treatment for this disease seems essential.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Fifteen New Zealand rabbits infected with Staphylococcus aureus (ATCC 25923) corneal ulcers were randomly divided into three groups of five for the present study. (I, II, and III). Group I was used as the control group (without treatment). The second group received an iodine solution (1.25%) without a nanoparticle structure (betadine). The third group received an iodine solution with a nanoparticle structure used as eye drops. Drops in the corneal ulcer group were used five times daily for 14 days.<\/jats:p>\n                <jats:p>Microbial counts and disease severity scores were measured on the first, second, fifth, and fourteenth days and compared between groups separately for each disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The results showed that the changes in microbial load were significant in the group that received betadine and nanoparticles. The microbial load was further reduced when using iodine nanoparticles than betadine. The betadine and nano-iodine groups significantly reduced the severity of the disease in rabbits with corneal ulcers (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The average changes in disease severity score were 4.8\u2009\u00b1\u20091.3, -2.6\u2009\u00b1\u20090.89, and -2.22\u2009\u00b1\u20091.22 in the untreated, nano iodine, and betadine groups, respectively. However, a significant increase in disease severity was observed in the untreated group (<jats:italic>p<\/jats:italic>\u2009=\u20090.001). It shows a significant difference (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) between the nano iodine, betadine, and untreated groups. However, the difference in disease severity changes between nano iodine and non-nano iodine groups was insignificant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Nanoparticle iodine is more effective than non-nanoparticle iodine in reducing bacterial load. In reducing the severity of the disease, both types of iodine were superior to no treatment. But there was no apparent difference between the two groups treated with iodine.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12348-023-00367-w","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:03:00Z","timestamp":1698332580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Investigating the effect of eye drops based on iodine nanoparticles in the treatment of corneal ulcers in rabbit eyes"],"prefix":"10.1186","volume":"13","author":[{"given":"Mostafa","family":"Feghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif","family":"Makhmalzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Masihpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Mortazavinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"2","key":"367_CR1","first-page":"373","volume":"2019","author":"GK Maree","year":"2019","unstructured":"Maree GK, Mirza AA, Admani MU, Talpur KI, Shaikh AA, Zeba N (2019) Frequency of risk factors of infectious keratitis in tertiary care hospital in hyderabad, Pakistan. Pak Armed Forces Med 2019(2):373","journal-title":"Pak Armed Forces Med"},{"key":"367_CR2","doi-asserted-by":"crossref","unstructured":"Gross J, Breitenbach J, Baumgartl H, Buettner R (2021). High-performance detection of corneal ulceration using image classification with convolutional neural networks. In: HICSS-54 Proceedings: 54th Hawaii International Conference on System Sciences (HICSS-54)","DOI":"10.24251\/HICSS.2021.415"},{"key":"367_CR3","unstructured":"Byrd LB, Martin N. Corneal ulcer. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023"},{"issue":"1","key":"367_CR4","first-page":"16","volume":"8","author":"Z Mohammad","year":"2019","unstructured":"Mohammad Z, Torbati PM, Asadi-Amoli F et al (2019) Microbiological profile of corneal ulcers at a tertiary referral center. Med Hypothesis Discov Innov Ophthalmol 8(1):16","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"2","key":"367_CR5","first-page":"128","volume":"15","author":"M Puig","year":"2020","unstructured":"Puig M, Weiss M, Salinas R, Johnson DA, Kheirkhah A (2020) Etiology and risk factors for infectious keratitis in South Texas. J Ophthalmic Vis Res 15(2):128","journal-title":"J Ophthalmic Vis Res"},{"issue":"4","key":"367_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jcjo.2017.11.001","volume":"53","author":"K Termote","year":"2018","unstructured":"Termote K, Joe AW, Butler AL et al (2018) Epidemiology of bacterial corneal ulcers at tertiary centers in Vancouver. BC Can J Ophthalmol 53(4):330\u2013336","journal-title":"BC Can J Ophthalmol"},{"issue":"4","key":"367_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1128\/jcm.15.4.635-639.1982","volume":"15","author":"RL Berkelman","year":"1982","unstructured":"Berkelman RL, Holland B, Anderson R (1982) Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 15(4):635\u2013639","journal-title":"J Clin Microbiol"},{"key":"367_CR8","doi-asserted-by":"publisher","first-page":"106064","DOI":"10.1016\/j.ijantimicag.2020.106064","volume":"56","author":"R Barreto","year":"2020","unstructured":"Barreto R, Barrois B et al (2020) Addressing the challenges in antisepsis: focus on povidone-iodine. Int J Antimicrob Agents 56:106064","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"367_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/ICU.0000000000000437","volume":"29","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Kanclerz P, Myers WG (2018) The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol 29(1):19\u201332","journal-title":"Curr Opin Ophthalmol"},{"issue":"12","key":"367_CR10","first-page":"548","volume":"7","author":"R Winkler","year":"2015","unstructured":"Winkler R (2015) Iodine\u2014a potent antioxidant and the role of Iodine\/Iodide in health and disease. Nat Sci 7(12):548","journal-title":"Nat Sci"},{"issue":"9","key":"367_CR11","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1021\/acs.molpharmaceut.6b00445","volume":"13","author":"S Liu","year":"2016","unstructured":"Liu S, Dozois MD, Chang CN et al (2016) Prolonged ocular retention of mucoadhesive nanoparticle eye drop formulation enables the treatment of eye diseases using significantly reduced dosage. Mol Pharm 13(9):2897\u20132905","journal-title":"Mol Pharm"},{"key":"367_CR12","doi-asserted-by":"publisher","first-page":"102112","DOI":"10.1016\/j.jddst.2020.102112","volume":"61","author":"UD Laddha","year":"2021","unstructured":"Laddha UD, Kshirsagar SJ (2021) Formulation of nanoparticles loaded in situ gel for treating dry eye disease: In vitro, ex vivo and in vivo evidence. J Drug Deliv Sci Technol 61:102112","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"367_CR13","first-page":"390","volume":"6","author":"H-Y Zhou","year":"2013","unstructured":"Zhou H-Y, Hao J-L, Wang S, Zheng Y, Zhang W-S (2013) Nanoparticles in the ocular drug delivery. Int J Ophthalmol 6(3):390","journal-title":"Int J Ophthalmol"},{"key":"367_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.addr.2017.04.001","volume":"122","author":"DR Janagam","year":"2017","unstructured":"Janagam DR, Wu L, Lowe TL (2017) Nanoparticles for drug delivery to the anterior segment of the eye. Adv Drug Deliv Rev 122:31\u201364","journal-title":"Adv Drug Deliv Rev"},{"key":"367_CR15","first-page":"1005","volume":"9","author":"A Hafner","year":"2014","unstructured":"Hafner A, Lovri\u0107 J, Lako\u0161 GP, Pepi\u0107 I (2014) Nanotherapeutics in the EU: An overview of current and future directions. Int J Nanomed 9:1005\u20131023","journal-title":"Int J Nanomed"},{"issue":"3","key":"367_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/jcm11030848","volume":"11","author":"E Pedrotti","year":"2022","unstructured":"Pedrotti E, Bonacci E, Kilian R, Pagnacco C, Fasolo A, Anastasi M et al (2022) The role of topical povidone-iodine in the management of infectious keratitis: a pilot study. J Clin Med 11(3):848","journal-title":"J Clin Med"},{"issue":"5","key":"367_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/01.ico.0000214220.67872.b1","volume":"25","author":"NZ Gregori","year":"2006","unstructured":"Gregori NZ, Schiffman JC, Miller DM, Alfonso EC (2006) A clinical trial of povidone-iodine (Betadine) versus placebo in the pretreatment of corneal ulcers. Cornea 25(5):558\u2013563","journal-title":"Cornea"},{"key":"367_CR18","first-page":"e919822","volume":"21","author":"P Bordin","year":"2020","unstructured":"Bordin P (2020) Corneal ulcer treated with 0.66% nanoemulsion povidone-iodine: a case report. Am. J. Med. Case Rep 21:e919822\u20131","journal-title":"Am. J. Med. Case Rep"},{"issue":"4","key":"367_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000217721","volume":"41","author":"CG Brozou","year":"2009","unstructured":"Brozou CG, Karabatakis V, Giannousis M, Mandraveli K, Karkavelas G, Alexiou-Daniel S (2009) The efficacy of intravitreal povidone-iodine application in experimental Staphylococcus epidermis endophthalmitis. Ophthalmic Res 41(4):181\u2013185","journal-title":"Ophthalmic Res"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-023-00367-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00367-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:03:27Z","timestamp":1698332607000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-023-00367-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1186\/s12348-023-00367-w","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"6 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted under the ethical code of IORC-0011. The anesthesia protocol included intramuscular injection of ketamine (30\u00a0mg\/kg), xylazine hydrochloride (10\u00a0mg\/kg), and local anesthesia of the eyes with tetracaine eye drops (0.5%). After the research, the rabbits were returned to the animal house.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}